tiprankstipranks
Trending News
More News >

Sutro Biopharma downgraded to Underperform from Buy at BofA

BofA analyst Tazeen Ahmad downgraded Sutro Biopharma (STRO) to Underperform from Buy with a price target of $1, down from $11.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1